HTA in the Czech Republic: Still Behind

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F19%3A00321407" target="_blank" >RIV/68407700:21460/19:00321407 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/978-981-10-9038-7_18" target="_blank" >https://doi.org/10.1007/978-981-10-9038-7_18</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-981-10-9038-7_18" target="_blank" >10.1007/978-981-10-9038-7_18</a>

Jazyk výsledku

angličtina

Název v původním jazyce

HTA in the Czech Republic: Still Behind

Popis výsledku v původním jazyce

The paper analyses the current state of HTA implementation and organisational initiatives in the Czech Republic. Although there have been some substantial ele-ments of HTA applied in the decision process of pharmaceutical reimbursement since 2008, HTA methods are rather disregarded in other technologies. Since there is practically no demand for HTA studies from payers and state representa-tives, HTA has been cultivated above all by interested individuals and small aca-demic research groups around them. These groups have succeeded in keeping pace with the global development both in theoretical and practical issues (among others in HTA methods for medical devices), however, the practical production of country specific HTA studies is rather rare. The main problem is non-existence of a national commonly accepted methodology and a legal framework. At least two attempts to establish a regular HTA process initiated by the Ministry of Health were destined to fail due to frequent personal changes in the Ministry. We discuss topical issues to be solved on the way to a national HTA system, and present our vision of a possible solution.

Název v anglickém jazyce

HTA in the Czech Republic: Still Behind

Popis výsledku anglicky

The paper analyses the current state of HTA implementation and organisational initiatives in the Czech Republic. Although there have been some substantial ele-ments of HTA applied in the decision process of pharmaceutical reimbursement since 2008, HTA methods are rather disregarded in other technologies. Since there is practically no demand for HTA studies from payers and state representa-tives, HTA has been cultivated above all by interested individuals and small aca-demic research groups around them. These groups have succeeded in keeping pace with the global development both in theoretical and practical issues (among others in HTA methods for medical devices), however, the practical production of country specific HTA studies is rather rare. The main problem is non-existence of a national commonly accepted methodology and a legal framework. At least two attempts to establish a regular HTA process initiated by the Ministry of Health were destined to fail due to frequent personal changes in the Ministry. We discuss topical issues to be solved on the way to a national HTA system, and present our vision of a possible solution.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

50602 - Public administration

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

World Congress on Medical Physics and Biomedical Engineering 2018 (Vol. 2)

ISBN

978-981-10-9037-0

ISSN

1680-0737

e-ISSN

—

Počet stran výsledku

5

Strana od-do

101-105

Název nakladatele

Springer Nature Singapore Pte Ltd.

Místo vydání

—

Místo konání akce

Prague

Datum konání akce

3. 6. 2018

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

000449742700018